Floatz logo

CIS-DIAMMINEDICHLOROPLATINUM II

HPV-Positive Oropharyngeal Squamous Cell Carcinoma

ImmunityBio, Inc.Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

16 Active assets in the HPV-Positive Oropharyngeal Squamous Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Cetuximab
National Cancer Institute (NCI)
Phase 1/2B
Irinotecan
AIDS Malignancy Consortium
Phase 1/2B
e7 tcr-t cells
Christian Hinrichs
Phase 2B
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER
Regeneron Pharmaceuticals
Phase 2CCC
Bms-907351
National Cancer Institute (NCI)
Phase 2CCC

View all 31 →

Same molecule, other indications

CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:

squamous cell lung carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
adenocarcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →